Annual report pursuant to Section 13 and 15(d)

Revenue - Revenue from Strategic Partnerships and Other License Agreements (Details)

v3.22.0.1
Revenue - Revenue from Strategic Partnerships and Other License Agreements (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]      
Revenues   $ 31,418 $ 29,323
AstraZeneca      
Disaggregation of Revenue [Line Items]      
Revenues $ 13,000 18,919 8,308
Seagen      
Disaggregation of Revenue [Line Items]      
Revenues   768 9,702
Servier      
Disaggregation of Revenue [Line Items]      
Revenues   4,070 11,313
Boston Pharmaceuticals      
Disaggregation of Revenue [Line Items]      
Revenues   5,711 0
Genentech      
Disaggregation of Revenue [Line Items]      
Revenues   $ 1,950 $ 0